Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis
- PMID: 24578540
- PMCID: PMC3939663
- DOI: 10.1136/bmjopen-2013-004275
Association of serum alkaline phosphatase with mortality in non-selected European patients with CKD5D: an observational, three-centre survival analysis
Abstract
Objectives: For characterisation of mineral bone disease in chronic kidney disease (CKD), laboratory surrogates have been suggested. This observational should investigate the association of total and skeletal alkaline phosphatase (AP) with mortality of patients undergoing maintenance renal replacement therapy.
Setting: Three renal outpatient centers in eastern-central Germany (secondary and tertiary care).
Participants: Complete survival and laboratory datasets were available in 407 of 493 patients. Age and gender distribution was equivalent to a general population with end-stage CKD (CKD5D). Patients were included between 2008 and 2010 if at least 2 weeks of maintenance treatment were documented.
Primary outcome measures: Mortality was estimated by setting the end of dialysis date as event date. Events other than death (change to another centre, life-sustaining renal function or transplantation) were censored.
Results: The OR to die within follow-up for patients in the higher of two total AP strata was 2.70 (95% CI 1.76 to 4.15). In univariate Kaplan-Meier analysis, total AP had a strong association with all-cause mortality (LogRank=24.1, p<0.001). Mean total AP and individual lowest skeletal AP, but not mean skeletal AP entered step-wise Cox models for survival from dialysis start (χ(2)=22.4; p<0.001) after adjusting for age, Kt/V, diabetes and vintage. Mean values of skeletal, total AP and parathyroid hormone were 14.8±8.9 µg/L, 91.9±55.3 U/L and 188±164 ng/L, respectively. Skeletal and total AP were highly correlated (R=0.86; p<0.001).
Conclusions: This unselected CKD5D population exhibited a clinical significant association of total AP with crude mortality and a stronger death risk association of total AP and individual lowest skeletal AP with crude mortality.
Keywords: Statistics & Research Methods.
Figures



References
-
- Lewis R. Mineral and bone disorders in chronic kidney disease: new insights into mechanism and management. Ann Clin Biochem 2012;49(Pt 5):432–40 - PubMed
-
- Stepan JJ, Lachmanova J, Strakova M, et al. Serum osteocalcin, bone alkaline phosphatase isoenzyme and plasma tartrate resistant acid phosphatase in patients on chronic maintenance hemodialysis. Bone Miner 1987;3:177–83 - PubMed
-
- Millán JL. Mammalian alkaline phosphatase: from biology to applications in medicine and biotechnology. Weinheim: Wiley, 2006
-
- Kobayashi I, Shidara K, Okuno S, et al. Higher serum bone alkaline phosphatase as a predictor of mortality in male hemodialysis patients. Life Sci 2012;90:212–18 - PubMed
-
- Fahrleitner-Pammer A, Herberth J, Browning SR, et al. Bone markers predict cardiovascular events in chronic kidney disease. J Bone Miner Res 2008;23:1850–8 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources